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Right heart catheterization was performed before and 
during long-term therapy with prazosin in 27 patients 
with severe chronic heart failure who underwent serial 
hemodynamic studies during 3 to 12 weeks of treatment 
with the drug. Doses of digoxin and furosemide remained 
constant during the trial; in addition, 11 of the 27 pa•
tients were assigned to concomitant therapy with spi•
ronolactone, while the remaining 16 patients did not 
receive the aldosterone antagonist. 
First doses of prazosin produced marked increases 
in cardiac index and marked decreases in mean arterial 
pressure, left ventricular filling pressure and systemic 
vascular resistance in both groups of patients (all p < 
0.01), but these effects became rapidly attenuated (p < 
0.01) in both groups after 48 hours and remained at•
tenuated during long-term therapy. After 3 to 12 weeks, 
values for cardiac index returned to pretreatment levels 
and did not decrease when the drug was withdrawn; 
values for mean arterial pressure, left ventricular filling 
pressure and systemic vascular resistance remained sig-
Although the sympathetic nervous system plays an impor•
tant role in the pathogenesis of the marked systemic vaso•
constriction that characterizes patients with congestive heart 
failure, the usefulness of alpha-adrenergic blockade with 
prazosin in the long-term management of these individuals 
remains controversial. Despite the dramatic enhancement 
of left ventricular performance that follows the administra•
tion of first doses of the drug (I), prolonged treatment with 
prazosin produces inconsistent long-term clinical benefits. 
Only one of the five randomized double-blind placebo-con-
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nificantly decreased (although attenuated) after 3 to 12 
weeks (p < 0.01) and increased to pretreatment values 
when the drug was withdrawn. The magnitude and time 
course of these responses were not altered by concomi•
tant therapy with spironolactone. Complete loss of 
hemodynamic efficacy (prazosin tolerance) was noted in 
14 (58%) of the 24 patients who underwent long-term 
hemodynamic study and was not accompanied by long•
term changes in plasma renin activity or body weight. 
These data indicate that prazosin produces long-term 
hemodynamic and clinical benefits in only 30 to 40% of 
patients with severe chronic heart failure and do not 
support a role for the renin-angiotensin system in the 
development of tolerance to alpha-adrenergic blockade. 
This low response rate explains why most randomized 
double-blind trials of prazosin in heart failure have not 
been able to demonstrate a significant difference between 
patients treated with placebo and those receiving active 
drug. 
(J Am Coli CardioI1986;7:671-80) 
trolled trials (2-6) that have been conducted to evaluate the 
drug's efficacy has shown a significant improvement in 
symptoms and exercise capacity after 1 to 12 months of 
treatment with prazosin compared with treatment with pla•
cebo. However, the mechanisms underlying the occurrence 
of drug failure during long-term alpha-adrenergic blockade 
remain incompletely elucidated, because in none of these 
controlled trials were serial hemodynamic and hormonal 
measurements performed, 
Previous uncontrolled hemodynamic studies (7-11) have 
suggested that the principal cause of treatment failure during 
long-term prazosin therapy is the development of hemo•
dynamic and clinical tolerance to the pharmacologic actions 
of the drug. Despite dramatic responses to initial doses of 
prazosin, repeated administration of the drug for 2 to 4 days 
is accompanied by a rapid loss of its hemodynamic effects 
(7-9). Whether such short-term attenuation persists during 
long-term treatment, however, and is responsible for the 
lack of sustained clinical efficacy in controlled clinical trials 
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remains unknown; the two reports (12,13) that have spe•
cifically examined this question disagree strongly in their 
findings. Furthermore, none of the studies that have eval•
uated the hemodynamic efficacy of long-term prazosin ther•
apy (2,6,11-20) has simultaneously allowed for the occur•
rence of circulatory changes related to intravascular 
instrumentation (21), kept diuretic drug dose constant and 
included a withdrawal phase at the end of treatment; there•
fore, these studies could not distinguish between hemody•
namic benefits related to prazosin from those attributable to 
protocol design. Few of these studies attempted to elucidate 
the mechanisms underlying the development of tolerance 
by measuring serial alterations in circulating hormones and, 
more important, by antagonizing the effects of these hor•
mones in an effort to prevent the development of tolerance. 
Finally, all previous long-term hemodynamic studies 
(2,6,11-20) treated only small numbers of patients and, 
thus, were limited in their ability to reach statistically jus•
tifiable conclusions. 
To address these issues, we performed sequential hemo•
dynamic and hormonal measurements during treatment with 
prazosin and after the withdrawal of long-term therapy with 
the drug in a large series of patients with severe chronic 
heart failure, in whom digitalis and diuretic drugs remained 
constant and in whom spironolactone was utilized to eval•
uate the contribution of the renin-angiotensin system to the 
development of tolerance to long-term alpha-adrenergic 
blockade. 
Methods 
Study patients. Our study group comprised 27 consec•
utive patients with severe chronic heart failure who received 
treatment with oral prazosin. There were 17 men and 10 
women, aged 44 to 81 years (mean 64). The cause of heart 
failure was ischemic heart disease in 13 patients, primary 
dilated cardiomyopathy in 13 patients and persistent left 
ventricular dysfunction after mitral valve replacement in 1 
patient; all patients had a left ventricular ejection fraction 
less than 30% by radionuclide ventriculography. All patients 
had symptoms at rest or on minimal exertion, but were 
studied during a period of clinical stability; none had ex•
perienced an acute myocardial infarction or an acute ex•
acerbation of congestive heart failure within 4 weeks. 
All patients were fed a 2 g sodium diet and received 
constant doses of digoxin and furosemide for at least 2 weeks 
before the trial. Seven to 14 days before the study, patients 
were hospitalized and immediately assigned to one of two 
treatment groups: the first 16 patients received no diuretic 
drugs other than furosemide for the treatment of heart fail•
ure, whereas the last 11 patients were treated with the al•
dosterone antagonist spironolactone, 150 mg orally daily, 
in addition to furosemide before and throughout the study. 
No patient in either group had received spironolactone within 
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the previous 2 months. All patients entered the trial after 
body weight and renal function remained unchanged for 3 
days on stable doses of digoxin and diuretic drugs. 
Hemodynamic measurements. At the end of the sta•
bilization period and after written, informed consent was 
obtained, right heart catheterization and arterial cannulation 
were performed for the measurement of intracardiac and 
systemic pressures, respectively. Patients were permitted to 
rest overnight before control hemodynamic determinations 
were made prior to the administration of prazosin, and all 
measurements were performed with the patient in a post•
prandial state. These guidelines were followed to minimize 
the occurrence of spontaneous hemodynamic changes that 
follow cardiac catheterization and meals in patients with 
congestive heart failure, which might mimic a vasodilator 
response (21). The performance of these invasive proce•
dures and hemodynamic measurements has been described 
in detail previously (21). Left ventricular filling pressure 
was measured as the pulmonary artery wedge pressure or 
as the pulmonary arterial diastolic pressure after its identity 
with wedge pressure was established. Cardiac output was 
determined by the thermodilution technique using iced 
injectate. 
Drug administration. On the day after intravascular in•
strumentation, after all medications (including digoxin and 
diuretic drugs) had been withheld, the following variables 
were measured repeatedly for at least 2 hours (with a vari•
ation of < 10%) to ensure stability of the pretreatment 
hemodynamic state before the administration of prazosin: 
mean arterial pressure, heart rate, left ventricular filling 
pressure, mean right atrial pressure and cardiac output. Each 
patient then received an initial dose of prazosin, 5 mg orally, 
followed by 5 mg of the drug every 8 hours. All hemo•
dynamic variables were measured before and every 30 min•
utes for 3 hours after the first dose of prazosin on day 1, 
the fourth dose of prazosin on day 2 and the seventh dose 
of prazosin on day 3, after which hemodynamic monitoring 
was discontinued. During this 48 hour period, patients con•
tinued to receive digoxin and diuretic drugs in unchanged 
doses, but these drugs were administered in the evening 
after completion of each day's hemodynamic measurements, 
so as not to interfere with assessment of the effects ofprazosin. 
Long-term therapy with prazosin. 5 mg three times daily, 
was then continued for 3 to 12 weeks (mean 6.2), during 
which time patients were fed a 2 g sodium diet and received 
the same doses of digoxin and diuretic drugs that they had 
been taking before the trial; no other vasodilator drugs were 
added. At the end of the treatment period, patients were 
readmitted to the hospital for 5 to 10 days to duplicate the 
conditions at the start of the study, after which right heart 
catheterization and arterial cannulation were performed for 
a second time during uninterrupted prazosin therapy using 
procedures identical to the first catheterization. The next 
morning, all hemodynamic variables were measured before 
JACC Vol 7, No 3 
March 1986,671-80 
and every 30 minutes for 3 hours after the patient's usual 
dose of prazosin (5 mg). Prazosin therapy was then abruptly 
withdrawn, and while digoxin and diuretic drugs were con•
tinued, all hemodynamic variables were reassessed every 
12 to 24 hours for the next 48 hours. 
Hormonal and clinical determinations. Blood samples 
were collected in each patient for determination of plasma 
renin activity (by radioimmunoassay) before the first dose 
of prazosin, 90 minutes after the first dose (on day I), after 
the seventh dose (on day 3), after the dose evaluated after 
3 to 12 weeks of treatment. and 48 hours after withdrawal 
of the drug. All samples were taken at the same time of 
day, with patients maintaining a 2 g sodium diet, 12 to 24 
hours after the last dose of diuretic drug and after at least 
4 hours in the supine position. 
The clinical status of each patient was evaluated during 
a control period of 3 days before institution of prazosin 
therapy and after 3 to 12 weeks of treatment with the drug, 
Changes in the severity of dyspnea and fatigue at rest, in 
exercise tolerance and in body weight were noted. Because 
all patients had symptoms at rest or on minimal exertion, 
formal exercise testing was not performed. 
Data analysis. Mean systemic pressure was determined 
by electronic filtration. Derived hemodynamic variables were 
calculated as follows: cardiac index = cardiac output/body 
surface area (liters/min per m2) and systemic vascular 
resistance = 80 X (MAP - MRAP)/cardiac output 
(dynes.s-cm - 5), where MAP = mean arterial pressure and 
MRAP = mean right atrial pressure, 
The responses to short- and long-term prazosin therapy 
were compared at five points: before prazosin, after the 
initial 5 mg dose of the drug, after 48 hours of therapy, 
during long-term drug administration (after 3 to 12 weeks) 
and 48 hours after drug withdrawaL At each point during 
therapy, hemodynamic variables were measured 90 ± 30 
minutes after the administration of prazosin, at the time of 
its peak effect on left ventricular filling pressure and sys•
temic vascular resistance. Changes in each hemodynamic 
variable and in plasma renin activity were compared at each 
of the five reference points by a repeated measures analysis 
of variance procedure in which Duncan's multiple range test 
was used to differentiate among significant responses, Qual•
itative and quantitative differences between subgroups of 
patients were evaluated by the t test for independent vari•
ables and the chi-square statistic using Yates' correction for 
continuity, respectively. Group data are expressed as mean 
± SEM. 
Definitions. The following hemodynamic definitions were 
used throughout the study. An initial response to the drug 
was defined as a 5 mm Hg or greater decrease in left ven•
tricular filling pressure or a 20% or greater decrease in 
systemic vascular resistance at peak effect compared with 
pre-prazosin values, In patients who demonstrated initial 
responses to the drug, we considered early hemodynamic 
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attenuation to have occurred when at least 50% of the initial 
decrease in left ventricular filling pressure and systemic 
vascular resistance was lost after 48 hours. A triphasic re•
sponse was identified when attenuated responses were ob•
served after 48 hours, but spontaneous restoration of drug 
effect was noted during long-term treatment, such that the 
responses observed after 3 to 12 weeks were similar to those 
observed after the first dose of the drug. Tolerance was 
defined when the hemodynamic variables measured after 3 
to 12 weeks of therapy had returned to pretreatment values. 
These definitions are similar to those used in previous hemo•
dynamic studies (22). 
Results 
Of the 27 patients who entered the trial, no patient dis•
continued therapy because of adverse reactions, but 3 pa•
tients died (1 wbo was pretreated with spironolactone and 
2 who were not). Each of the remaining 24 patients com•
pleted the study and underwent all hemodynamic, biochem•
ical and clinical evaluations, 
Overall short- and long-term hemodynamic responses. 
First doses of prazosin produced marked increases in cardiac 
index (p < 0.01), but repeated administration of the same 
dose of the drug resulted in a rapid and complete loss of its 
initial effect on this variable (p < 0.01) after 48 hours. 
Values for cardiac index returned to pretreatment levels 
during long-term therapy with prazosin and did not decrease 
when the drug was withdrawn (Fig. I). 
Figure 1. Values for cardiac index (CI), mean arterial pressure 
(MAP), heart rate (HR), left ventricular filling pressure (LVFP), 
mean right atrial pressure (MRAP) and systemic vascular resistance 
(SVR) before prazosin (C), after the first dose of the drug (D I ), 
after 48 hours of therapy (D3)' during long-term treatment (3 to 
12 weeks, LT) and 48 hours after drug withdrawal (W). Symbols 
indicate Significance of differences from control values; p values 
at the top of each panel indicate significance of differences between 
DI and LT. Data are shown as mean:±: SEM. 
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First doses of prazosin produced marked decreases in 
mean arterial pressure, left ventricular filling pressure, mean 
right atrial pressure and systemic vascular resistance (p < 
0.01); the magnitude of these effects became partially but 
significantly (p < 0.01) attenuated after 48 hours and re•
mained partially attenuated to a similar degree after 3 to 12 
weeks. Compared with pretreatment values, the decreases 
in mean arterial pressure, left ventricular filling pressure, 
mean right atrial pressure and systemic vascular resistance 
during long-term prazosin therapy were modest but signif•
icant (p < 0.01); all four variables returned to control values 
when prazosin was withdrawn. No significant changes in 
heart rate were noted at any time during the study. The 
hemodynamic state 48 hours after the withdrawal of long•
term prazosin therapy was similar to that seen before the 
first dose of the drug. 
Individual hemodynamic patterns of response. All 27 
patients responded hemodynamically to the first dose of 
prazosin with a decrease in left ventricular filling pressure 
of at least 5 mm Hg or a decrease in systemic vascular 
resistance of at least 20%. After 48 hours of prazosin ther•
apy, however, 16 of the 27 patients showed a loss of at 
least 50% of the decrease in systemic vascular resistance 
and in left ventricular filling pressure seen with first doses 
of the drug (early attenuation), whereas 11 patients showed 
persistent effects on one or both of these variables. Of the 
16 patients who showed early hemodynamic attenuation, 3 
died during the study and 10 showed persistent loss of ef•
ficacy after 3 to 12 weeks of therapy (long-term tolerance); 
only 3 patients showed spontaneous restoration of effect 
during prolonged treatment after the occurrence of an early 
attenuated response (triphasic response) (12,22). Long-term 
tolerance developed in 14 (58%) of the 24 patients who 
completed the trial, 4 of whom did not show early hemo•
dynamic attenuation but demonstrated loss of efficacy only 
after 3 to 12 weeks of treatment. 
Overall, 10 (37%) of 27 patients improved hemodynam•
ically during long-term prazosin therapy; withdrawal of the 
drug at the end of the study for 48 hours resulted in sig•
nificant hemodynamic deterioration in 9 of these 10 re•
sponders but in only I of the 14 nonresponders who were 
still alive. The 10 responders and 17 nonresponders did not 
differ with respect to pretreatment hemodynamic and clin•
ical variables. 
OveraU hormonal and clinical responses. Plasma renin 
activity increased significantly after the first dose and after 
48 hours of prazosin, but decreased to control values after 
3 to 12 weeks of treatment and did not decrease when the 
drug was withdrawn (Fig. 2). Weight did not change during 
the course of therapy (68.8 ± 2.8 to 68.6 ± 2.8 kg); 
although it increased by more than 2 kg in four patients, it 
decreased by more than 2 kg in five patients. Hemodynamic 
responders and nonresponders did not differ with respect to 
changes in plasma renin activity or in body weight during 
10 
r 8 I-
> 
I-u_ 
<t ~ 6 ~ z .... 
ZE w .... 
a:: 0' 4 
<tS 
;:;;: 
(f) 
<t 
...J 2 
CL 
o 
* * I I 
JACC Vol 7. No 3 
March 1986671-80 
.-.~ 11 T 
. l"'r 
1 1 
LT W 
*P<OI 
Figure 2. Values for plasma renin activity before, during treat•
ment with and after the withdrawal of prazosin in the 24 patients 
who completed the trial. Format and abbreviations as in Figure I. 
long-term treatment; there was no relation between changes 
in plasma renin activity or in body weight and changes in 
any hemodynamic variable. 
Nine (33%) of 27 patients improved clinically during 
long-term prazosin therapy, 8 of whom responded hemo•
dynamically after 3 to 12 weeks of treatment. Therapy was 
complicated by transient dizziness after the first dose of 
prazosin in one patient and by edema formation in three 
patients. each of whom gained more than 2 kg during the 
trial. 
Effect of spironolactone on clinical and hemodynamic 
responses. The 11 patients who received spironolactone did 
not differ from the 16 patients who did not with respect to 
pretreatment clinical, hemodynamic or hormonal variables 
(Table I). Both groups of patients showed similar and marked 
increases in cardiac index with first doses of prazosin; car•
diac index returned to control values after 48 hours in both 
groups and showed little further change during long-term 
treatment and after withdrawal of the drug (Fig. 3). Both 
groups of patients showed similar and marked decreases in 
left ventricular filling pressure, mean right atrial pressure, 
mean arterial pressure and systemic vascular resistance with 
initial administration of prazosin, which became partially 
attenuated after 48 hours and after 3 to 12 weeks of therapy; 
these variables returned to pretreatment values in both groups 
when prazosin was withdrawn (Fig. 4 to 6). Neither group 
showed significant changes in heart rate during the trial. 
There was no significant difference between the two groups 
in the magnitude of drug-induced changes in any hemo•
dynamic variable at any time during the study. Individually, 
long-term tolerance developed in 6 (60%) of the 10 patients 
pretreated with spironolactone who completed the trial and 
in 8 (57%) of the 14 patients who received only digoxin 
and diuretic drugs in addition to prazosin for 3 to 12 weeks. 
Three (27%) of the II patients pretreated with spirono-
lACC Vol 7. No 3 
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Table 1. Pretreatment Hemodynamic and Climcal Characteristics of Patients Who Received 
ConcomItant Therapy With Spironolactone and Those Who Oid Not 
With Without 
SpIronolactone Spironolactone 
(n = II) (n = 16) P Values 
Age (yr) 63.5 ± 2,4 64.8 ± 3,4 NS 
Sex (M/F) 714 10/6 NS 
Caw,e of heart failure ICM (7), PDC (4) ICM (6), PDC (9), MVR (I) NS 
WeIght (kg) 66.7 ± 4.3 67.2 ± 38 NS 
Plasma renIn actiVIty 5.7 ± 2.0 6.1 ± 3.7 NS 
(ng/ml per h) 
CardIac index I 71 ± 0.16 193±0.13 NS 
(IIter,/mm per me) 
Mean artenal pressure 807 ± 27 847 ± 32 NS 
(mm Hg) 
Left ventricular fillIng 26.3 ± 20 26.8 ± I 5 NS 
pres,ure (mm Hg) 
Mean nght atnal 11 5 ± 25 II 7 ± I I NS 
pressure (mm Hg) 
Heart rate 83.8 ± 34 899 ± 47 NS 
(beat>/mm) 
S y'>lemlc va,cular 1.958 ± 171 1,864 ± 130 NS 
re,l,tance 
( dyne,·,·cm ') 
F = female, ICM = IschemIC cardIOmyopathy; M = male. MVR = mItral valve replacement for valvular 
heart dlsea,e, PDC = pnmary dilated cardiomyopathy Number of patients with each diagnosb is deSIgnated 
m parentheses The p values m last column de'lgnate sIgnIficance of dIfference, between the two groups, where 
NS = not '>lgnIficant. 
lactone and 6 (38%) of the 16 patients who did not receive 
the aldosterone antagonist improved clinically during long•
term prazosin therapy. Neither group showed significant 
changes in weight (67.0 ± 4.7 to 65.8 ± 5.0 kg in patients 
who received spironolactone; 70.2 ± 3.5 to 70.6 ± 
3.3 kg in patients who did not). Plasma renin activity in-
Figure 3. Values for cardiac index before, dunng treatment WIth 
and after the withdrawal of prazosin in patients grouped accordmg 
to concomItant therapy with spironolactone. The p values indicate 
significance of differences between 0 1 and 0, m each group. 
Format and abbreviations as in Figure I. 
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creased significantly after first doses of prazosin in both 
groups (4.0 ± 1.1 to 7.7 ± 2.5 ng/ml per h in patients 
who received spironolactone; 2.4 ± 1.0 to 5.9 ± 2.1 ng/ml 
per h in patients who did not; both p < 0.05), but this did 
not persist in either group during long-term treatment (3.9 
± 1.2 and 2.3 ± 0.9 ng/ml per h, respectively). None of 
Figure 4. Values for left ventricular filling pressure before, during 
treatment WIth and after the withdrawal of prazosin in patients 
grouped according to concomitant therapy with spironolactone. 
The p values indicate sIgnificance of differences between 0 1 and 
0, in each group. Format and abbreviations as in Figure I. 
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Figure S. Values for mean arterial pressure before, during treat•
ment with and after the withdrawal of prazosin in patients grouped 
according to concomitant therapy with spironolactone. The p val•
ues indicate significance of differences between 0 1 and 0 3 in each 
group. Format and abbreviations as in Figure 1. 
the observed differences in the clinical or hormonal re•
sponses to prazosin in the two groups was significantly 
different. 
Discussion 
Our findings indicate that despite marked hemodynamic 
responses to first doses of the drug, the long-term admin•
istration of prazosin produces only modest hemodynamic 
and clinical improvement in patients with congestive heart 
failure. Only 30 to 40% of our patients showed notable 
amelioration of symptoms after 3 to 12 weeks of treatment, 
and their clinical state deteriorated significantly when the 
drug was withdrawn. In contrast, in most of our patients, 
values for hemodynamic variables during long-term pra•
zosin therapy were similar to those seen before initiation of 
treatment, and its withdrawal produced no adverse hemo•
dynamic or clinical effects. Although other investigators 
(3,11,23,24 r have suggested that tolerance to prazosin is 
related to activation of the renin-angiotensin system and 
associated aldosterone-mediated fluid retention, the rapid 
and sustained loss of drug efficacy that we observed in our 
study was not related to increases in plasma renin activity 
or in body weight and could not be prevented by concomitant 
treatment with aldosterone antagonists. These findings do 
not support a role for the renin-angiotensin system in the 
development of tolerance to long-term alpha-adrenergic 
blockade in patients with chronic heart failure. 
Comparison of present results with previous hemo•
dynamic studies. Previous reports by ourselves (7) and 
other investigators (8,9) suggested several years ago that 
the initial beneficial hemodynamic effects of prazosin in 
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Figure 6. Value, for systemic vascular resistance before, during 
treatment with and after the withdrawal of prazosin in patients 
grouped according to concomitant therapy with spironolactone. 
The p values indicate Significance of differences between 0 1 and 
O} in each group. Format and abbreviations as in Figure I. 
patients with heart failure became rapidly attenuated after 
several days of treatment; however, the importance of these 
observations remained unclear, because most of the early 
uncontrolled clinical experience with the drug was highly 
favorable (1,23), and long-term hemodynamic studies gen•
erall y showed sustained beneficial effects (J 2 ,15-17). In an 
attempt to reconcile these differences, Awan et al. (12) 
suggested that the short-term hemodynamic attenuation that 
we and others observed after 2 to 4 days was a transient 
phenomenon and that long-term treatment (for 4 weeks) 
resulted in the spontaneous restoration of the effect of the 
drug. Such an explanation received widespread acceptance 
as long as prazosin was considered to be useful, but this 
hypothesis proved difficult to support when double-blind 
randomized clinical trials (2,4-6) failed to show significant 
differences between patients treated with prazosin and those 
treated with placebo for 1 to 12 months. The results of the 
present study are in direct conflict with those of A wan et 
al. (12,23), who believed that the loss of efficacy observed 
during short-term prazosin therapy was a transient reversible 
event. The early hemodynamic attenuation that we noted in 
our patients with heart failure generally persisted during 
long-term treatment with the drug; only 10 to 15% of pa•
tients showed spontaneous restoration of responsiveness during 
the course of therapy with prazosin, a frequency similar to 
that seen with other vasodilator drugs (22). Long-term tol•
erance developed in nearly 60% of our patients and was the 
principal reason for drug failure. Given a placebo response 
rate in patients with heart failure of nearly 20 to 25% (25,26), 
the low frequency (30 to 40%) of long-term hemodynamic 
benefits with prazosin in our study explains why most ran•
domized double-blind trials have not demonstrated a sig-
JACC Vol. 7, No 3 
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nificant difference between placebo-treated and actively treated 
patients (2-6), 
We believe that differences in study design explain why 
our findings concerning the long-term efficacy of prazosin 
in heart failure differ from those of previous reports, Many 
early studies utilized exercise duration, echocardiography 
and radionuclide ventriculography to document clinical ben•
efits (1,23,27), but exercise tolerance commonly improves 
after placebo therapy (25.26.28) and noninvasive measures 
of cardiac performance correlate poorly with invasively de•
rived hemodynamic variables (29,30). In several hemody•
namic studies (6,11.14-16.18, 19) doses of diuretic drugs 
were generally increased during treatment with prazosin to 
prevent fluid retention. and this practice may have contrib•
uted to the long-term hemodynamic benefits noted in these 
reports (18,31); we kept doses of digoxin and diuretic drugs 
constant. Previous investigators administered prazosin within 
hours after right heart catheterization at a time when patients 
with heart failure are in a transiently vasoconstricted state. 
the dissipation of which closely mimics a vasodilator drug 
response (21). Similar degrees of systemic vasoconstriction 
may not be provoked during a second catheterization pro•
cedure (32) and, hence. hemodynamic data obtained at that 
time will usually show values for ventricular filling pressures 
and systemic vascular resistance that are lower than those 
measured before initiation of treatment. Such hemodynamic 
responses will be interpreted as a favorable effect of therapy 
even if the drug is exerting no beneficial actions; the con•
tribution of treatment to the hemodynamic changes observed 
at the time of the second catheterization can onl y be assessed 
if the drug is withdrawn at the completion of the triaL a 
procedure that generally was omitted in previou~ reports 
(2,6.12-15.17-20). We did not perform hemodynamic 
measurements until 24 hours after right heart catheterization 
(to minimize instrumentation-related artifacts) and con•
firmed the magnitude of drug effect after 3 to 12 weeks by 
drug withdrawal. It is of interest, therefore. that the only 
previous study that took similar precautions in study design 
noted short- and long-term hemodynamic responses to pra•
zosin similar to those seen in our patients ( 13). and previous 
studies that evaluated the effects of prazosin withdrawal 
observed clinical response rates similar to ours (16.33). 
Long-term tolerance to prazosin did not develop in all 
of our patients with congestive heart failure, and it did not 
develop similarly with respect to all hemodynamic vari•
abies. With first doses of prazosin. 21 of 27 patients showed 
an increase in cardiac index of at least 20%. and all 27 
patients showed a decrease in left ventricular filling pressure 
of at least 5 mm Hg. During long-term treatment. however. 
only 3 patients showed sustained increases in cardiac index. 
but 10 patients showed sustained decreases in left ventricular 
filling pressure. Accordingly. prazosin produced no long•
term increases in cardiac index in our group as a whole. 
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but did produce modest but significant long-term decreases 
in right and left ventricular filling pressures. These findings 
suggest that pharmacologic tolerance developed preferen•
tially to the arterial dilating actions of prazosin; similar 
findings have been reported by other investigators 
(8.15.16.18.34) during short- and long-term therapy with 
the drug. In addition, once pharmacologic tolerance is es•
tablished. the withdrawal of prazosin restores responsive•
ness to the drug more rapidly and completely in the venous 
than in the arterial circulation (10). These observations may 
result from differences between systemic arteries and veins 
in the distribution and kinetics of alpha-adrenergic receptor 
sUbpopulations (35.36). 
Role of renin-angiotensin system in the development 
of prazosin tolerance. Other studies (3,11,23.24) have 
suggested that activation of the renin-angiotensin system is 
the principal mechanism responsible for the development 
of tolerance to long-term prazosin therapy in patients with 
congestive heart failure. Such activation may be a direct 
result of antagonism of the intrarenal alpha-adrenergic re•
ceptors that inhibit renin release (37.38) or an indirect result 
of a prazosin-induced redistribution of blood flow away from 
the kidneys (39,40). Regardless of its mechanism. the re•
sultant increase in circulating angiotensin II serves to limit 
the acute hypotensive actions of prazosin and may thereby 
lead to rapid attenuation of the short-term effects of alpha•
blockade (41,42). Should such hormonal activation persist 
during prolonged therapy. similar antagonism of the long•
term vasodilating effects of prazosin might be expected to 
occur. Furthermore, sodium retention secondary to angio•
tensin-mediated hyperaldosteronism may not only increase 
ventricular filling pressures by expanding intravascular vol•
ume but may also decrease the responsiveness of the pe•
ripheral vasculature to alpha-adrenergic blockade (10 .11). 
Each of these mechanisms. alone or in combination, could 
be responsible for long-term hemodynamic and clinical tol•
erance to prazosin. Unfortunately. there has been little con•
sistent support for these concepts. Although increases in 
plasma renin activity (3) or in plasma aldosterone (11) have 
been noted by some investigators during long-term prazosin 
therapy in patients with heart failure. they have not been 
observed by others (4.13,43); the sustained increases in 
plasma renin activity reported in a single study (3) were 
small in magnitude and may have resulted from increments 
in the dose of concomitantly administered diuretic drugs and 
not from an effect of the drug. Furthermore. although so•
dium retention and weight gain frequently develop during 
long-term treatment with prazosin (3,5.6.12.15,19.24,40,43), 
they may not be related to activation of the renin-angiotensin 
system (43-46) and may also occur during treatment with 
placebo (6,46); more important, attenuation of the hemo•
dynamic responses to alpha-adrenergic blockade is seen in 
the absence of changes in plasma volume and body weight 
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(7,13,20,34). Finally, although concomitant treatment with 
spironolactone has been claimed to prevent sodium retention 
and avert the development of long-term tolerance to pra•
zosin, there is only anecdotal support for this approach. 
Our findings do not support a major role for the renin•
angiotensin system in the development of long-term hemo•
dynamic and clinical tolerance to prazosin in heart failure. 
Although plasma renin activity increased significantly after 
first doses of the drug, long-term treatment was accompa•
nied by a return of values for plasma renin activity to the 
pretreatment state. Because renin stimulation by prazosin is 
probably mediated by blockade of alpha-adrenergic recep•
tors' similar to those that mediate systemic vasoconstriction 
(37,38), attenuation of the hormonal effects of the drug 
developed parallel to the development of tolerance to its 
hemodynamic actions; similar findings have been reported 
by other investigators (34). Furthermore, it is unlikely that 
intravascular volume expansion occurred during the course 
of our trial and served to attenuate hemodynamic respon•
siveness, because weight did not increase significantly dur•
ing long-term prazosin therapy in our patients, and ventric•
ular filling pressures after the withdrawal of prazosin were 
not greater than were those seen before initiation of treat•
ment with the drug. Finally, the hemodynamic responses to 
short- and long-term prazosin therapy were unaffected by 
concomitant treatment with spironolactone; aldosterone an•
tagonism did not prevent the occurrence of hemodynamic 
and clinical tolerance in our patients or in the experience 
of others (13). The benefits previously reported from ad•
junctive therapy with spironolactone probably resulted from 
its independent diuretic actions and not from a synergistic 
effect with prazosin. Further studies are necessary, how•
ever, to determine whether circulating levels of angiotensin 
II may directly oppose the actions of prazosin (42); such an 
effect would be resistant to spironolactone and would require 
long-term converting enzyme inhibition to restore respon•
siveness to alpha-adrenergic blockade. 
Alternative mechanisms for the development of tol•
erance to prazosin. Other mechanisms have been proposed 
to explain the development of tolerance to prazosin in pa•
tients with chronic heart failure, but these have also been 
difficult to support. Although some reports (16,17) have 
suggested that progression of the underlying heart disease 
may closely mimic tolerance, our observations on with•
drawal of the drug indicate that progression did not occur 
and could not account for the return of hemodynamic vari•
ables to pretreatment values during long-term therapy. Other 
investigators (8,46,47) have postulated that impaired ab•
sorption or enhanced metabolic inactivation of prazosin dur•
ing long-term treatment may account for loss of efficacy, 
but plasma levels of the drug after the development of tol•
erance are higher than after the administration of first doses. 
Still others have proposed that the large doses of prazosin 
utilized in the treatment of heart failure exert blocking ef-
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fects on both alpha,- and alpharadrenergic receptors (48,49); 
blockade of alphaz-receptors (normally inhibitory to pe•
ripheral norepinephrine release) results in a marked eleva•
tion of plasma levels of catecholamines (11,14,34,43,48), 
which may lead to the development of pharmacologic tol•
erance by overwhelming the postsynaptic adrenergic block•
ade induced by the drug (43,44,46). We did not measure 
plasma norepinephrine in our patients, but the lack of long•
term hemodynamic and clinical efficacy in previous studies 
(4,46) could not be explained by changes in circulating 
levels of catecholamines. 
The physiologic and pharmacologic mechanisms under•
lying the development of tolerance of long-term alpha-ad•
renergic blockade remain unknown. Tolerance may involve 
an alteration in the number or affinity, or both, of postsyn•
aptic alpha-adrenergic receptors (46,47,50), but direct mea•
surement of radio ligand binding sites has revealed no change 
in alpha,-receptor density and affinity during experimentally 
induced tolerance to prazosin in the rabbit (46). Alterna•
tively, alpha-adrenergic responsiveness in vascular tissue 
may be regulated in both animals and in humans at a post•
receptor site (46,50), which may undergo significant mod•
ification during sustained alpha-blockade and may account 
for the loss of efficacy during long-term prazosin therapy. 
Precautions and limitations. Our findings need to be 
interpreted cautiously. We did not evaluate a control group 
of patients (not treated with prazosin) in the present study 
to ensure that the hemodynamic changes that we observed 
were the result of drug therapy. Utilizing an identical pro•
tocol design, however, we (32) and other investigators 
(2,6,51,52) have not observed hemodynamic changes in the 
absence of effective treatment in other studies; furthermore, 
the hemodynamic state after the withdrawal of prazosin 
during long-term therapy in our patients was similar to that 
seen before initiation of treatment with the drug. Our pri•
mary objectives were to investigate the fate of the hemo•
dynamic attenuation seen early during treatment with pra•
zosin and to determine whether spironolactone can prevent 
the development of long-term tolerance to the drug; the 
control groups we utilized were suitable to address these 
questions. 
Another limitation of the present study is that we eval•
uated the short- and long-term hemodynamic effects of pra•
zosin only at rest and not during exercise. Rubin et al. (53) 
first suggested in a short-term hemodynamic study that at•
tenuation of the effects of prazosin may occur only at rest 
and not during exertion; similar results were noted by Gold•
man et al. (27) during long-term treatment with the drug. 
Both groups of investigators postulated that, in view of the 
alpha-adrenergic blocking properties of prazosin, the drug's 
effects may be apparent only during states of high sympa•
thetic activity (such as physical effort); others (54,55), how•
ever, have been unable to support this hypothesis. Indeed, 
the marked increase in plasma catecholamines that accom-
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panies exertion would be expected to overwhelm any com•
petitive drug-induced alpha-adrenergic blockade; hence, the 
effects of prazosin might be expected to be less apparent 
during effort. Regardless of the validity of these concepts, 
all of the hemodynamic studies that have evaluated the ef•
fects of long-term treatment with prazosin have noted re•
sponses during exercise that have closely paralleled those 
seen at rest (2,6,14,15,20.56); when tolerance developed 
to the hemodynamic effects of the drug at rest, it was also 
evident during exertion (2,20,56). Hence, randomized dou•
ble-blind trials (2,4,6,56) have failed to show significant 
differences in the long-term hemodynamic response to ex•
ercise between patients treated with prazosin and those treated 
with placebo; therefore, exercise capacity did not improve 
during prazosin therapy in these studies. Consequently. we 
do not believe that our findings would be altered significantly 
had we conducted hemodynamic measurements during ex•
ercise as well as at rest. 
Conclusions. Our findings indicate that the marked 
hemodynamic attenuation seen early in the course of therapy 
with prazosin in patients with severe chronic heart failure 
generally persists during long-term treatment with the drug 
and is the principal cause of drug failure. Such long-term 
tolerance was not accompanied by changes in plasma renin 
activity or in body weight and could not be prevented by 
concomitant treatment with aldosterone antagonists; hence. 
these observations do not support a role for the renin-an•
giotensin system in the development of pharmacologic tol•
erance to long-term alpha-adrenergic blockade. Our finding 
that only 30 to 40% of patients with heart failure treated 
with prazosin show notable long-term hemodynamic ben•
efits explains why most randomized double-blind clinical 
trials (4-8) have failed to show significant differences be•
tween placebo-treated and actively treated patients. 
We are indebted to the nurses, cardiology fellow, and ,taff of the Ames 
and Rose Cardiac Care Umts for the excellent care they provided for the 
patIents in thiS study 
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